Close

Cannabis-based products for medicinal use

Reading Time: 7 minutes In November 2018 the Home Office released a draft Guideline scope for Cannabis-based products for medicinal use in which they announced that specialist doctors (like consultant neurologists) on the Special Register of the General Medical Council will be able to prescribe cannabis-based medicinal products to some patients. Before this, the only cannabis-based medicines licensed for…

What’s the story with CuATSM

Reading Time: 5 minutes There has recently been a flood of news stories on the outcomes of the Australian Phase 1 clinical trial investigating Copper ATSM (CuATSM) which is a small man-made compound that can selectively deliver copper to cells. The results were first presented at our International Symposium in Glasgow back in December. MND is a terrible disease…

Tirasemtiv not found effective for treatment of MND

Tirasemtiv not found effective for treatment of MND

Reading Time: 2 minutes In their official press release published on 21 November 2017, Cytokinetics Inc. announced that they will not be continuing work on tirasemtiv after disappointing results in the latest Phase 3 clinical trial. The trial, known under the acronym ‘VITALITY-ALS’, tested whether the drug has a beneficial effect on the breathing function and muscle strength of…

Lighthouse Project shines a beacon on HERVs and their role in ALS

Reading Time: 3 minutes There is recent evidence to suggest that Human Endogenous Retroviruses (HERVs) may be involved in amyotrophic lateral sclerosis (ALS). HERV-K has been directly linked to motor neurone damage and has been found in the brain tissue of patients with ALS. The MND Association recently awarded a small grant to fund part of the ‘Lighthouse Project’…